Video

Christopher Schneck, MD: Early Interventions for Bipolar Disorder

Author(s):

There remains a need for better treatments for bipolar disorder when it is identified early.

There remains significant gaps in treatment for patients with bipolar disorder, particularly when the disease is identified early.

In a presentation during the 2022 Annual Psychiatric Times™ World CME Conference in San Diego on August 12, Christopher Schneck, MD, Professor of Psychiatry, University of Colorado HIV Clinic, talked about how we can improve treatment strategies when bipolar disorder is identified early.

“Really this is thinking about what groups who have not fully developed bipolar disorder can we stage an intervention,” Schneck said. “And thinking about both psychopharmaceutic interventions and psychotherapeutic interventions. There really isn’t much out there in the literature.”

In combat these gaps in care, Schneck said there have been a number of recent studies involving both adult patients with bipolar disorder and pediatric patients as well.

He also said studies have looked at siblings of patients with bipolar disorder.

“The way families interact with each other has a great influence on a child’s developmental process and ultimately the development or not of the mood disorder.”

Schneck said there is a 12 session model for treatment in which he will educate both the patient and families about the illness and how to effectively communicate with each other.

Related Videos
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Wei Zhang, MD, PhD: Naltrexone’s GI, Liver Safety for Alcohol Use Disorder Treatment
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
© 2024 MJH Life Sciences

All rights reserved.